Kenju Ando, Tateaki Naito, Satoshi Hamauchi, Keita Miura, Yuichiro Nishibori, Ayumi Tonsho, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Hiroaki Kodama, Michitoshi Yabe, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ko Ryo, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Kentaro Yamazaki, Toshiaki Takahashi
BACKGROUND: Anamorelin is a selective ghrelin receptor agonist approved for cancer cachexia in Japan. Little is known about predictors of anamorelin efficacy. This study aimed to assess the effect of diabetes on the efficacy and safety of anamorelin in patients with cancer cachexia. METHODS: Medical records of patients with advanced non-small-cell lung, gastric, pancreatic, or colorectal cancer who received anamorelin between January 2021 and March 2023 were retrospectively reviewed...
May 9, 2024: International Journal of Clinical Oncology